Enteropathy-associated T-cell lymphoma medical therapy

Enteropathy-associated T-cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Enteropathy-associated T-cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Enteropathy-associated T-cell lymphoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Enteropathy-associated T-cell lymphoma medical therapy
CDC on Enteropathy-associated T-cell lymphoma medical therapy
Enteropathy-associated T-cell lymphoma medical therapy in the news
Blogs on Enteropathy-associated T-cell lymphoma medical therapy
Risk calculators and risk factors for Enteropathy-associated T-cell lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

Enteropathy-associated T-cell Lymphoma (EATL), also enteropathy-type T-cell lymphoma (ETTL), is a type of T-cell non-hodgkin lymphoma that affects the small intestine, it is composed of large lymphoid cells. Enteropathy-associated T-cell lymphoma has two subtypes, type I enteropathy-associated T-cell lymphoma which has a strong association with celiac disease and it is more common in western countries and type II enteropathy-associated T-cell lymphoma which is mostly found among the Asian population. Genes involved in the pathogenesis of this disease include 8q24, T-cell receptor (TCR) beta and gamma, and 16q genes. On gross pathology, multiple intestinal ulcers are characteristic findings of EATL. On microscopic histopathological analysis, monotonous cells, round or angulated vesicular nuclei, and prominent nucleoli are characteristic findings of enteropathy-associated T-cell lymphoma. There are no established causes for enteropathy-associated T-cell lymphoma. EATL must be differentiated from other diseases such as peptic ulcer, poorly-differentiated adenocarcinoma, MALT lymphoma, diffuse large B cell lymphoma, and mantle cell lymphoma.

Treatment

Medical Therapy

• There is no treatment for enteropathy-associated T-cell lymphoma; the mainstay of therapy is supportive care.
• The optimal therapy for enteropathy-associated T-cell lymphoma depends on the extent and the location of the lymphoma in the small intestine.
• Stem cell transplant can be helpful in those patients that are in remission phase of disease.

Treatment of enteropathy-associated T-cell lymphoma

Therapy	Description
Supportive therapy	People often need nutritional support A gluten-free diet is also recommended
Surgery	May be an option Done to remove the damaged small intestine
Chemotherapy	May be offered to people who can tolerate it: Following surgery When the cancer cannot be removed by surgery or is extensive Combination chemotherapy is often used for this aggressive lymphoma Drug regimen: (CHOP) Cyclophosphamide AND Doxorubicin AND Vincristine AND Prednisone